# Intraperitoneal Infusion of ex Vivo-cultured Allogeneic NK Cells in Recurrent Ovarian Carcinoma Patients

> **NCT03539406** · PHASE1 · COMPLETED · sponsor: **Radboud University Medical Center** · enrollment: 11 (actual)

## Conditions studied

- Recurrent Ovarian Carcinoma
- Recurrent Fallopian Tube Carcinoma
- Recurrent Primary Peritoneal Carcinoma

## Interventions

- **BIOLOGICAL:** UCB-NK cells
- **DRUG:** Chemotherapy

## Key facts

- **NCT ID:** NCT03539406
- **Lead sponsor:** Radboud University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-04
- **Primary completion:** 2023-05-01
- **Final completion:** 2023-09-01
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2024-08-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03539406

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03539406, "Intraperitoneal Infusion of ex Vivo-cultured Allogeneic NK Cells in Recurrent Ovarian Carcinoma Patients". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03539406. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*